UCB SA reported a 79% surge in adjusted EBITDA to €2.64 billion for fiscal 2025, fueled by robust growth from its Bimzelx product, which saw net sales climb over 200% to €2.23 billion. However, the headline 34% margin included proceeds from asset sales and contract manufacturing windfalls, which when excluded, revealed a weaker underlying 31.4% margin. Revenue rose 26% to €7.74 billion, driven by Bimzelx becoming the company's largest product, with significant contributions from the U.S. market where sales reached €1.66 billion.